Table 7.
Effect of Tadalafil on Total IPSS and IPSS-QOL
| Observation Period | Measured Value | Mean Change From Baseline | |||||
|---|---|---|---|---|---|---|---|
| n | Mean | SD | n | Mean | 95% CI | ||
| Total IPSS | Baseline | 1150 | 15.8 | 6.9 | − | − | − |
| 1M | 861 | 12.5 | 6.5 | 818 | −3.4 | −3.8 to –3.1 | |
| 3M | 717 | 11.3 | 6.1 | 685 | −4.5 | −5.0 to –4.1 | |
| 6M | 701 | 11.2 | 6.3 | 663 | −4.7 | −5.1 to –4.2 | |
| 12M | 577 | 11.1 | 6.5 | 553 | −4.7 | −5.2 to –4.2 | |
| 18M | 485 | 11.0 | 6.2 | 467 | −5.0 | −5.6 to –4.4 | |
| LOCF | 1063 | 11.5 | 6.8 | 988 | −4.3 | −4.7 to –3.9 | |
| IPSS-QOL | Baseline | 1149 | 4.2 | 1.1 | − | − | − |
| 1M | 856 | 3.4 | 1.4 | 815 | −0.9 | −1.0 to –0.8 | |
| 3M | 718 | 3.0 | 1.3 | 686 | −1.2 | −1.3 to –1.1 | |
| 6M | 702 | 2.8 | 1.4 | 664 | −1.4 | −1.5 to –1.3 | |
| 12M | 580 | 2.8 | 1.3 | 554 | −1.5 | −1.6 to –1.3 | |
| 18M | 484 | 2.7 | 1.3 | 465 | −1.5 | −1.6 to –1.4 | |
| LOCF | 1059 | 3.0 | 1.4 | 989 | −1.3 | −1.4 to –1.2 | |
Abbreviations: CI, confidence interval; IPSS, International Prostate Symptom Score; LOCF, last observation carried forward; M, month(s); n, number of patients analyzed; QOL, quality of life; SD, standard deviation.